LIFECORE BIOMEDICAL, INC. \DE\
Lifecore is a contract development and manufacturing organization based in Chaska, Minnesota. It serves pharmaceutical, biotechnology and medical device customers, providing product development, cGMP manufacturing and aseptic filling of complex sterile injectable products in syringes, vials and cartridges. Its services include analytical and formulation development, process scale-up, clinical study materials, testing, packaging, warehousing and distribution. Lifecore manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid using bacterial fermentation, supplying it in bulk and in formulated injectable products. It also develops and manufactures highly viscous sterile injectables that do not use hyaluronic acid. Its three facilities in Chaska support production of drug and device products, with five aseptic filling lines. Lifecore earns business through customer contracts ranging from supplying raw materials and development services to manufacturing finished products and managing supply-chain responsibilities.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LFCR in the last 7 days.
No SEC Form 4 filings for $LFCR in the last 30 days.
See all $LFCR insider activity →Lifecore Biomedical announced regulators granted early termination of the HSR Act waiting period for its proposed merger, effective November 4, 2026. The merger still requires other approvals and shareholder adoption of the agreement. According to the company, this clears one closing condition.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger
Lifecore Biomedical (LFCR) reported Q2 EPS of -$1.08, missing estimates by $0.82, with revenue at $25.32M, below the $27.37M consensus. The stock is up 28.14% over 3 months but down 5.02% year-over-year. InvestingPro rates its financial health as 'good performance'.
Recent LFCR coverage spans mergers & acquisitions, earnings and corporate actions.
Regulatory clearance reduces deal uncertainty and may lift the stock.
The termination removes a regulatory hurdle, increasing the probability of deal completion and supporting the stock.
Earnings miss likely triggers sell pressure.
Earnings miss and widening loss suggest near‑term downside pressure.
Earnings miss and widening loss likely weigh on the stock.
AlphAI scores every news story that mentions LFCR with an AI model for sentiment and relevance, and aggregates insider trades from LIFECORE BIOMEDICAL, INC. \DE\'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lifecore Biomedical announced regulators granted early termination of the HSR Act waiting period for its proposed merger, effective November 4, 2026. The merger still requires other approvals and shareholder adoption of the agreement. According to the company, this clears one closing condition.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger
Lifecore Biomedical (LFCR) reported Q2 EPS of -$1.08, missing estimates by $0.82, with revenue at $25.32M, below the $27.37M consensus. The stock is up 28.14% over 3 months but down 5.02% year-over-year. InvestingPro rates its financial health as 'good performance'.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026 , and Provides Corporate Update -- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., November 4, 2026 -- Lifecore Biomedical, Inc. (NASDAQ:
Lifecore Biomedical (LFCR) reported Q3 2026 revenues of $25.3M, down 18.6% YoY. Net loss was $40.1M, or $1.08 per share. CEO Paul Josephs highlighted new business wins, including projects with top pharmaceutical and biotech companies, expected to contribute to long-term revenue growth. Adjusted EBITDA was $4.0M, up $1.0M YoY. The company ended Q3 with $38.0M in liquidity.
Lifecore Biomedical set Nov. 4, 2026 as the record date for a special meeting to vote on its merger agreement. Stockholders of record on that date will vote at the meeting. The company will file proxy statements with the SEC. According to the company, proxy materials will be available on sec.gov and its investor relations site.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “
Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Lifecore Biomedical, LLC (“Lifecore”), a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement (the “Third Amen
Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for up to $663.7 million. The deal offers $6.28 per share plus a CVR, representing a 49.5% premium. The transaction, expected to close in Q4 2026, requires shareholder and regulatory approvals. Lifecore's stock will be delisted post-closing.
